- Hello, Jeff...
-
- Well, here's yet another vaccine getting the fast track
to market. Notice that C. Difficile is a big problem in Europe and North
America and that translates into big bucks. The people most affected are
senior citizens and those with illnesses. M O N E Y, the company, Sanofi
Pasteur stands to make a lot of it. It's ALL ABOUT M O N E
Y!
-
- Patty
-
-
- FDA grants C. difficile vaccine candidate fast-track
designation
-
- InfectiousDiseaseNews.com
- 11-16-10
-
- The FDA has granted Sanofi-Pasteur's investigational
Clostridium difficile vaccine candidate fast-track designation for the
treatment of C. difficile.
-
- "Our C. difficile vaccine candidate is in phase
2," Michel DeWilde, PhD, senior vice president of research and development
at Sanofi-Pasteur, said in a press release. "The FDA fast-track designation
recognizes that a C. difficile vaccine could address an important unmet
medical need."
-
- The incidence of C. difficile infection has increased
significantly in recent years in North America and Europe. Treatments in
these two regions of the world are estimated to be costing more than $7
billion a year. The current treatment of C. difficile infection involves
the use of one of the two antibiotics recommended for the management of
C. difficile.
-
- Under this program, the FDA can accept for review completed
portions of the licensing application before receipt of the entire application,
according to DeWilde.
|
